Inozyme Pharma to Present at the BofA Securities 2021 Virtual Healthcare Conference
Inozyme Pharma, a biopharmaceutical company focused on rare diseases, announced that CEO Axel Bolte will participate in a fireside chat at the BofA Securities 2021 Virtual Healthcare Conference on May 13 at 11:45 a.m. ET. The event will be available via live webcast on Inozyme’s website, with a replay accessible for 90 days post-event. Inozyme develops innovative therapeutics targeting diseases caused by abnormal mineralization, specifically focusing on ENPP1 and ABCC6 Deficiencies. The company aims to address the underlying causes of these rare genetic conditions.
- None.
- None.
BOSTON, May 06, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc., a rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced that its co-founder, president, and CEO, Axel Bolte, MSc, MBA, will participate in a fireside chat at the BofA Securities 2021 Virtual Healthcare Conference on Thursday, May 13, at 11:45 a.m. ET.
The fireside chat will be webcast live and can be accessed from the Investor & News section of Inozyme’s website under Events. An archived replay of the webcast will be available for up to 90 days following the event.
About Inozyme Pharma
Inozyme Pharma (Nasdaq: INZY) is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue, and skeleton. Through our in-depth understanding of the biological pathways involved in mineralization, we are pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. It is well established that two genes, ENPP1 and ABCC6, play key roles in a critical mineralization pathway and that defects in these genes lead to abnormal mineralization. We are initially focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies.
Inozyme Pharma was founded in 2017 by Joseph Schlessinger, Ph.D., Demetrios Braddock, M.D., Ph.D., and Axel Bolte, MSc, MBA, with technology developed by Dr. Braddock and licensed from Yale University. For more information, please visit www.inozyme.com.
Contacts
Investors:
Inozyme Pharma
Stefan Riley, Director of Investor Relations
Stefan.riley@inozyme.com
Media:
SmithSolve
Alex Van Rees
(973) 442-1555 ext. 111
Alex.vanrees@smithsolve.com
FAQ
What event will Inozyme Pharma participate in on May 13, 2021?
Who is the CEO of Inozyme Pharma?
How can I watch the Inozyme Pharma fireside chat?
What is Inozyme Pharma's focus area in biopharmaceuticals?
What diseases is Inozyme Pharma targeting?
